trial

Assessment of Schizophrenia Patients' Clinical Study Experiences

NCTId NCT05948111
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Not Yet Recruiting
Enrollment 500 (estimated)
Sponsored by Power Life Sciences Inc.
Primary completion 2025-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Not Yet Recruiting
Enrollment
500 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2024-08
Primary completion
2025-08
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
—

Sponsors

Power Life Sciences Inc.Lead Sponsor

Investigators

1
Michael B GillStudy Director

Sites

1 total
San Francisco, United States

Facts & assertions

4 sourced
Enrollment
500
Phase
NA
Primary Completion Date
2025-08
Status
NOT_YET_RECRUITING
relationships
The graph out of here
lead_sponsor
Power Life Sciences Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Michael B Gill
person